-
Daiichi Sankyo Presents First Snapshot Analyses from Global ETNA-AF Programme of Oral, Once-daily LIXIANA®▼ (edoxaban) in Patients with Nonvalvular Atrial Fibrillation in Routine Clinical PracticeDaiichi Sankyo2020-08-03 09:37:28Daiichi Sankyo Presents First Snapshot Analyses from Global ETNA-AF Programme of Oral, Once-daily LIXIANA®▼
-
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AMLDaiichi Sankyo2020-08-03 09:37:57FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s FLT3 Inhibitor Quizartinib for
-
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug ConjugateDaiichi Sankyo2018-11-15 08:38:42Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
-
Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyo’s Quizartinib Significantly Prolongs Overall Survival as Single Agent Compared to Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD MutationsDaiichi Sankyo2018-11-15 08:38:42Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyo’s Quizartinib Significantly Prolongs Overall Survival as
-
Daiichi Sankyo to Present Late-Breaking Phase 3 Data for Single Agent Quizartinib in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations at Plenary Session at EHA 2018Daiichi Sankyo2018-11-15 08:38:42Daiichi Sankyo to Present Late-Breaking Phase 3 Data for Single Agent Quizartinib in Patients with
-
Daiichi Sankyo Presents Phase 3 ENLIVEN Study of Pexidartinib, Demonstrating Statistically Significant Clinical Improvement Across Multiple Endpoints in Patients with Tenosynovial Giant Cell Tumor at 2018 American Society of Clinical Oncology (ASCO) AnnuaDaiichi Sankyo2018-11-15 08:38:42Daiichi Sankyo Presents Phase 3 ENLIVEN Study of Pexidartinib, Demonstrating Statistically Significant
-
Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with Advanced HER2-Overexpressing or HER2-Mutated Non-Squamous Non-Small Cell Lung CancerDaiichi Sankyo2019-10-15 11:36:06Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with Advanced HER2-Overexpressing or
-
Daiichi Sankyo Presents Long-Term Phase 1 Results of Antibody Drug Conjugate DS-8201 in Patients with HER2-Expressing Breast, Gastric and Other Solid Cancers at 2018 American Society of Clinical Oncology (ASCO) Annual MeetingDaiichi Sankyo2018-11-15 08:38:42Daiichi Sankyo Presents Long-Term Phase 1 Results of Antibody Drug Conjugate DS-8201 in Patients with
-
Daiichi Sankyo Presents Preliminary Phase 1 Data for Antibody Drug Conjugate U3-1402 in Patients with HER3-Expressing Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual MeetingDaiichi Sankyo2019-10-15 11:22:44Daiichi Sankyo Presents Preliminary Phase 1 Data for Antibody Drug Conjugate U3-1402 in Patients with
-
Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug DevelopmentDaiichi Sankyo2018-11-15 08:38:42Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development
